3,163
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

, , , , , , , , ORCID Icon, , & show all
Pages 111-122 | Received 22 Mar 2019, Accepted 02 Aug 2019, Published online: 18 Sep 2019

References

  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Rockville, MD: US Department of Health and Human Services; 2018. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed January 22, 2019.
  • Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11–19.
  • Vitoria M, Ford N, Doherty M, Flexner C. Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings. Antivir Ther. 2014;19(suppl 3):31–37.
  • Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Curr Opin HIV Aids. 2015;10(4):246–252.
  • Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
  • Spreen WR, Margolis DA, Pottage J. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8(6):565–571.
  • Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14(5):192–203.
  • Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2013;57(11):5472–5477.
  • Edurant [package insert]. Titusville, NJ: Janssen Therapeutics;2011; revised 2017. https://www.janssencarepath.com/sites/www.janssencarepath.com/files/prescribing-information-edurant.pdf. Accessed January 22, 2019.
  • Williams PE, Crauwels HM, Basstanie ED. Formulation and pharmacology of long-acting rilpivirine. Curr Opin HIV Aids. 2015;10(4):233–238.
  • Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006;9(5):320–333.
  • Romaine J, Murray M, Bradley C. Psychometric evaluation of the revised HIV Treatment Satisfaction Questionnaire (HIVTSQ). Abstract presented at: Annual European Congress of the International Society For Pharmacoeconomics and Outcomes Research; October 29–November 2, 2016; Vienna, Austria.
  • The Health Psychology Research Group. HIVTSQ Guidelines. London: Royal Holloway of the University of London; 2015.
  • Simoni JM, Beima-Sofie K, Mohmed ZH, Collier AC, Ho R. Acceptability of long-acting injectable ART: provider and patient preferences. Poster presented at Adherence 2017; June 4–6, 2017; Miami, FL.
  • Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One. 2018;13(1):e0190487.
  • World Health Organization (WHO) Support for Country Impact. Progress Report 2016: Prevent HIV, Test and Treat All. Geneva: WHO; 2016. http://www.who.int/hiv/pub/progressreports/2016-progress-report/en. Accessed January 22, 2019.